What question did this study set out to answer?

This review aims to evaluate contemporary therapeutic strategies for myeloproliferative neoplasms and suggest approaches for personalized treatment.

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

View Full Paper

Ask AI

Bookmark

Authors

Review appraises therapeutic options and outcomes for myeloproliferative neoplasms, indicating a need for personalized treatment strategies.

This review aims to evaluate contemporary therapeutic strategies for myeloproliferative neoplasms and suggest approaches for personalized treatment.
Appraised the diversity and number of therapeutic strategies for myeloproliferative neoplasms.
Discussed the importance of optimizing treatment sequencing and combination therapies based on patient-specific needs.
Explored considerations for clinical trial design focusing on long-term disease stability and patient outcomes.
Emphasizes the need for a shift in clinical trial endpoints towards longer-term disease modification.
Identifies growing approval rates for novel therapies within clinical settings.
Highlights the importance of personalized treatment strategies due to the heterogeneity among patients.

Ngo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Review appraises therapeutic options and outcomes for myeloproliferative neoplasms, indicating a need for personalized treatment strategies.